Leiden, The Netherlands, October 29, 2007. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that it has completed randomized treatments in its North American clinical trial assessing the safety and efficacy of Rhucin® (recombinant human C1 inhibitor) to treat acute attacks of hereditary angioedema (HAE). The Company plans to continue an open label study with Rhucin® for hereditary angioedema patients at sites across the United States and Canada.
